Not Yet RecruitingPhase 1/2

Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy

Poland90 participantsStarted 2026-06-01

Plain-language summary

This clinical study aims to evaluate the safety and preliminary therapeutic potential of mesenchymal stem cell-derived therapies in patients diagnosed with spinocerebellar palsy. The investigational treatment includes neuroinduced mesenchymal stem cells and their derived exosomes administered via intravenous and intranasal infusion.

Who can participate

Age range18 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Clinical diagnosis of spinocerebellar palsy confirmed by neurological examination; Disease duration ≤10 years; Ability to provide informed consent. Exclusion Criteria: Severe systemic illness; Active infection; History of malignancy within 5 years; Prior stem cell therapy; Pregnancy or breastfeeding.

What they're measuring

MDS-UPDRS

Timeframe: 92 weeks

SARA

Timeframe: 92 weeks

Trial details

NCT IDNCT07467733

SponsorBiocells Medical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-06-01

Contact for this trial

Andrei Peskau

+48452365311 info@biocellsmedical.com

View on ClinicalTrials.gov More Spinocerebellar Ataxia - All Sub-types trials